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Abstract Ridaforolimus (AP23573; MK 8669) is an analog of sirolimus and a small
molecule inhibitor of the mammalian target of rapamycin for the treatment of
cancer. Both intravenous and oral formulations of the compound are being
tested in clinical trials for the treatment of soft-tissue and bone sarcomas. It is
in phase III development for sarcoma in the EU and US, and phase II for
breast cancer, endometrial cancer, non-small cell lung cancer, and prostate
cancer in the US and other markets in the world. This review discusses the key
development milestones and therapeutic trials of this drug.
1. Introduction
Merck& Co. are developing ridaforolimus, an
analog of sirolimus and a small molecule inhibi-
tor of themammalian target of rapamycin (mTOR),
for the treatment of cancer. mTOR is a protein
kinase that controls cell growth by regulating many
cellular processes, including protein synthesis and
autophagy. Compared with other mTOR inhibi-
tors, ridaforolimus is not a prodrug and has shown
in vivo stability. Both intravenous and oral for-
mulations of the compound are being tested in
clinical trials for the treatment of various solid
tumors and hematologic malignancies. The initial
indication is soft-tissue and bone sarcomas.
ARIAD Pharmaceuticals, the compound’s ori-
ginator, considered developing ridaforolimus for
use in drug-eluting stents to prevent restenosis, in
conjunction with balloon angioplasty.
1.1 Company Agreements
InMay 2010, ARIAD andMerck restructured
their July 2007 collaboration agreement for rida-
forolimus, so that Merck has the exclusive license
to develop, manufacture, and commercialize the
compound in oncology.Merck will assume respon-
sibility and costs for all ridaforolimus activities,
including clinical trials and regulatory filings.Merck
will make an upfront cash payment of $US50mil-
lion to ARIAD and will reimburse ARIAD for its
ridaforolimus expenses incurred since 1 January
2010, estimated at approximately $US19 million.
The transfer of all ridaforolimus activities toMerck
is expected to take 6 months, and Merck will re-
imburse ARIAD for all its ridaforolimus costs
incurred until the transfer is completed. ARIAD
will be eligible to receive up to $US514 million in
regulatory and sales milestones, based on success-
ful commercialization in multiple indications. This
includes $US65 million in milestones associated
with the potential sarcoma indication ($US25
million for acceptance of a new drug application
[NDA] by the US FDA, $US25 million for US
registration, $US10 million for European regis-
tration and $US5 million for Japanese registra-
tion), and $US200 million in milestones based on
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achievement of significant sales thresholds. Merck
will book global sales and pay ARIAD tiered
double-digit royalties on global net sales. In ad-
dition to now receiving royalties on US sales in
lieu of a profit split, these global royalty rates are
approximately one-third greater than the rates
ARIAD would have received for ex-US sales under
the original collaboration agreement. ARIAD will
have an option to co-promote ridaforolimus with
up to 20% of the sales effort for the product in all
indications in the US, and Merck will compensate
ARIAD for its sales efforts. Milestones associated
with the start of four phase III trials ($US74.5
million) in indications other than sarcoma and
the development-cost advance contemplated by the
original collaboration agreement are not included
in the revised agreement. The terms for develop-
ment and commercialization of ridaforolimus in
potential non-oncology indications remain subject
to future agreement between the companies.[1,2]
In July 2007, ARIAD entered into a global col-
laboration agreement with Merck, to jointly de-
velop and commercialize ridaforolimus for the
treatment of cancer. Each party would fund 50%
of the cost of global development of ridaforo-
limus, except that Merck would fund 100% of
the cost of ex-US development specific to the de-
velopment or commercialization of the drug out-
side the US. In certain circumstances, either party
could opt-out of conducting and funding certain
late-stage clinical development, which would result
in changes in development and commercialization
responsibilities and compensation arrangements.
Both companies would share overall responsi-
bility for global commercialization and develop-
ment of ridaforolimus. In the US, ARIAD would
distribute and sell ridaforolimus for all cancer
indications and book all sales, and ARIAD and
Merck would co-promote and would each receive
50% of the income from such sales. Outside the
US, Merck would distribute, sell, and promote
ridaforolimus and book all sales;Merck would pay
ARIAD tiered double-digit royalties on such end-
market sales of ridaforolimus. On a global basis,
ARIAD would be responsible for manufacturing
the active pharmaceutical ingredient used in the
product, and Merck would be responsible for the
formulation of the finished tablets. In the US,
ARIAD would have primary responsibility for
development of ridaforolimus for metastatic sarco-
ma. Merck and ARIAD would have joint respon-
sibility in theUS for development of all other cancer
indications being pursued. Outside the US, Merck
would have primary responsibility for development
in all cancer indications being pursued.[3]
ARIAD entered into two licensing agreements
for ridaforolimus for potential cardiovascular
indicationswithMedinol (January 2005) and ICON
Medical Corporation (October 2007) to develop
and commercialize stents and other medical devices
to deliver ridaforolimus for use in vascular dis-
ease. Under the terms of the agreements, ARIAD
granted these companies non-exclusive, world-
wide, royalty-bearing licenses under its patents
and technology related to ridaforolimus to de-
velop, commercialize, and sell stents and certain
other medical devices to deliver ridaforolimus.
ARIAD would supply ridaforolimus for use in
development, manufacture, and sale of the stents
and other medical devices. It also retained the
right to enter into one additional non-exclusive
licensing agreement in this area.
1.2 Key Development Milestones
1.2.1 Breast Cancer
A phase II trial (NCT00736970) is being con-
ducted to evaluate the safety and efficacy of rida-
forolimus in combination with trastuzumab
(Herceptin) in patients with metastatic, HER2-
positive breast cancer who have developed re-
sistance to trastuzumab. The study has enrolled
37 patients in Chile, the US, and the EU, and
initial data showed that the trial met its primary
endpoint of objective response rate.[4-6]
1.2.2 Endometrial Cancer
In August 2008, ARIAD initiated a phase II
clinical trial (NCT00739830) assessing the safety
and efficacy of oral ridaforolimus in patients with
metastatic or recurrent endometrial cancer fol-
lowing first-line chemotherapy, comparing rida-
forolimus with progestin. The primary endpoint
will be progression-free survival (PFS). ARIAD
will receive a $US2.5 million milestone payment
from Merck upon the treatment of the first pa-
tient.[7] Enrollment of 150 patients from the US,
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EU, Asia, and Australia is ongoing as of June
2010.
ARIAD Pharmaceuticals has presented results
from its phase II study (NCT00122343) of rida-
forolimus monotherapy (12.5mg, 30 minute intra-
venous infusion for 5 consecutive days every
other week for 28-day cycles) in 45 patients with
progressive metastatic endometrial cancer despite
prior chemotherapy; the trial met its primary
endpoint, and achieved single-agent activity in
the treatment of endometrial cancer. The study
was conducted in the US and Europe. Subjects
were monitored for at least 6 months after en-
rollment, and could continue on ridaforolimus if
they had clinical benefit.[8,9]
1.2.3 Non-Small Cell Lung Cancer
A phase II trial (NCT00818675) of ridaforoli-
mus in patients with advanced non-small cell lung
cancer (NSCLC) who have not responded to two
prior treatment regimens was initiated by Merck
and ARIAD in February 2009. The randomized,
double-blind trial will compare ridaforolimus
against placebo in patients with a KRASmutation,
a mutation in lung tumors that is recognized as a
predictor of poor response to endothelial growth
factor receptor inhibitors. All patients will receive
four 10mg tablets of ridaforolimus once daily for
5 consecutive days each week during an 8-week
lead-in treatment period. Patients with partial re-
sponse will continue on ridaforolimus until dis-
ease progression. Any patients with stable disease
will be randomized to receive ridaforolimus or
placebo until disease progression. The primary
endpoint is PFS in the randomized population.
The trial will enroll 150 patients at approximately
38 sites including medical centers in the US and
Europe.[10] Enrollment of patients is ongoing as
of June 2010.
Ridaforolimus has demonstrated potent single-
agent, anti-tumor activity in preclinical models of
NSCLC with a KRAS mutation.[11]
1.2.4 Prostate Cancer
Merck has initiated a double-blind, random-
ized, phase II trial (NCT00777959) in the US and
other countries, to compare oral ridaforolimus in
combination with bicalutamide versus placebo
and bicalutamide in patients with asymptomatic,
metastatic, androgen-independent prostate can-
cer. The primary endpoint is a 30% decrease in
prostate specific antigen compared to baseline
within 12 weeks of treatment.[12] The study en-
rolled 156 patients.
A phase II trial (NCT00110188) of ridaforo-
limus monotherapy has been completed in patients
with advanced refractory prostate cancer. The
trial is being conducted at multiple US centers in
approximately 38 patients. Patient enrollment was
completed in the first quarter of 2006. The agent
was administered using a weekly intravenous
dosing regimen.[13,14]
Positive preclinical data on ridaforolimus in
combination with bicalutamide in prostate can-
cer models have been reported.[15,16]
1.2.5 Sarcoma
ARIAD has completed enrollment in its multi-
national, phase III trial of oral ridaforolimus
in patients with metastatic soft-tissue and bone
sarcomas. The pivotal SUCCEED (SarcomamUlti-
Center Clinical Evaluation of the Efficacy of
Deforolimus; NCT00538239) trial is assessing
PFS as the primary endpoint and overall survival
as a secondary endpoint, in patients with meta-
static sarcomas following a favorable response to
chemotherapy. Approximately 650 patients world-
wide were randomized to ridaforolimus or placebo.
An independent Data Monitoring Committee
has now completed the final second interim ana-
lysis, and has recommended that the trial con-
tinue to its final analysis without modification.
This second interim analysis was triggered by the
achievement of two-thirds of the prescribed PFS
events, and final data analysis is expected in the
fourth quarter of 2010. ARIAD has reached an
agreement on a Special Protocol Assessment with
the US FDA for the SUCCEED trial, and the
European Medicines Agency (EMA) has provided
protocol advice consistent with that of the FDA, as
part of its Protocol Assistance programme.[1,17-21]
Merck plans to file for approval of ridaforo-
limus for the treatment of sarcoma in the US in
2010.[22]
In March 2010, Merck and ARIAD com-
menced a phase II study (NCT01010672) evaluating
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maintenance therapy with ridaforolimus in patients
with metastatic or soft-tissue sarcoma. This non-
randomized, open-label study is expected to
enroll approximately 50 patients in Japan.
ARIAD has conducted a phase II trial
(NCT00093080) of intravenously administered
ridaforolimus as a single agent among patients
with relapsed and/or refractory sarcomas. The non-
randomized, multicenter trial recruited 212 pa-
tients from the US and Europe, who were divided
into four well defined subgroups, characterized
by tumor type. Clinical benefit response (CBR) rate,
the primary endpoint, was achieved in patients
with the three most prevalent types of sarcoma
(bone sarcoma, leiomyosarcoma, and liposarcoma).
Additional positive efficacy data from a phase II
trial in 61 evaluated patients with advanced sar-
coma were presented in November 2006.[23-25]
Ridaforolimus was designated fast-track sta-
tus by the FDA for the treatment of soft-tissue
and bone sarcomas in April 2005. ARIAD will
pursue treatment of soft-tissue and bone sarco-
mas as the initial registration path for rida-
forolimus. The compound also received orphan
drug status for the same indications from the
FDA and EMA in August and November 2005,
respectively.[26-28]
1.2.6 Various Advanced Cancers
In March 2010, Merck and ARIAD initiated
a phase I study (NCT01071304) to evaluate the
effect of multiple oral doses of ridaforolimus
40mg, on the single-dose pharmacokinetics of
midazolam. The trial will enroll approximately 16
patients with advanced solid tumors, lymphoma,
or hematologic malignancies that have failed to
respond to standard therapy, have progressed
despite standard therapy, or for which standard
therapy does not exist.
Merck and ARIAD have initiated a phase I
clinical trial (NCT00781846) to assess oral rida-
forolimus in combination with intravenous bev-
acizumab in patients with advanced cancers. This
trial will assess the safety, tolerability, and recom-
mended phase II dose in approximately 17 pa-
tients from the US. Patient recruitment has been
completed, with results presented in September
2009.[5,29-31]
Merck has completed a phase I trial
(NCT00874731) to assess the effect of ridaforo-
limus on corrected QT interval in patients with
advanced cancer. A total of 23 patients partici-
pated in this study conducted in the US.
A phase Ib trial (NCT00288431) has been
completed, evaluating an oral formulation of rida-
forolimus plus doxorubicin in patients with
advanced cancer, particularly those with soft-tissue
sarcomas as well as breast, ovarian, and endo-
metrial cancers. The trial was initiated in Febru-
ary 2006 at three US sites enrolled 37 patients.[32]
ARIAD initiated a phase I/IIa trial (AP23573-05-
106; NCT00112372) in May 2005, to investigate
seven different dosage regimens of oral ridaforo-
limus in approximately 150 patients with relapsed
or refractory cancers. This study was completed
in March 2009. Pharmacokinetic and pharma-
codynamic results have been reported.[33,34]
Intravenous ridaforolimus (as a single agent)
is in a phase I/II clinical trial (SUNSHINE;
NCT00704054) in pediatric patients (aged 1–17
years) with advanced solid tumors. The US-based
trial is being sponsored by the Pediatric Cancer
Foundation. Approximately 36 subjects are ex-
pected to be recruited into the study.[31,35]
A phase I combination trial (MK8669-004;
NCT00730379) of ridaforolimus and dalotuzu-
mab in patients with advanced cancer is ongoing
in the US. The study has completed enrollment of
87 patients and is designed to determine the tox-
icity profile, maximum tolerated dose and recom-
mended phase II dose.
Ridaforolimus plus dalotuzumab (an anti-insulin-
like growth factor [IGF]-1R monoclonal anti-
body) synergistically enhanced anti-tumor activity,
in vivo and in vitro. The results serve to confirm the
‘vertical-pathway synergy’ and blocking of feed-
back signaling between IGF-1R and mTOR.[11]
1.3 Patent Information
ARIAD Pharmaceuticals was issued US Patent
No. 7 091 213 inAugust 2006, which provides cover-
age for ridaforolimus and family of structurally re-
lated compounds, as well as their medical uses
through to the year 2023. Related patents are pend-
ing in the US and major markets outside the US.[36]
168 Adis R&D Profile
ª 2010 Adis Data Information BV. All rights reserved. Drugs R D 2010; 10 (3)
2. Scientific Summary
2.1 Pharmacokinetics
In 129 evaluable patients receiving oral rida-
forolimus, maximum plasma concentration (Cmax)
occurred at 2–3 hours and the median terminal
elimination half-life (t½) was 35–70 hours. Rida-
forolimus showed a rapid exponential decline
followed by a slower linear phase of elimination.
Mean estimated area under the concentration-
time curve (AUC) and Cmax increased in a less
than dose-proportional manner. Absolute bio-
availability derived from data for intravenous
ridaforolimus estimates it to be 20%.[34]
Combined phase I data showed that daily and
weekly dosing regimens of ridaforolimus displayed
a highly predictable and reproducible blood-
clearance profile with a median t½ of 49 hours for
all evaluable patients with various types of ad-
vanced solid tumors.[37]
In a phase I dose-escalation trial involving
24 patients with refractory or advancedmalignancies,
preliminary pharmacokinetic analyses showed
a median Cmax for ridaforolimus of 98.5 ng/mL




Updated preliminary clinical data fromaphase II
studywith oral ridaforolimus (40mg/day, once daily
for 5 days) in combination with trastuzumab in 34
patients with resistant, metastatic HER2-positive
breast cancer showed that 26 patients were dis-
continued from the trial, 13 due to progressive dis-
ease, 7 due to adverse events, and two patients died
(one death was from an intestinal perforation and
was possibly drug related). The safety profile of the
combination was consistent with previous single-
agent data and there were no new safety signals.[4,5]
2.2.2 Endometrial Cancer
Preliminary phase II results indicated that
ridaforolimusmonotherapy was well tolerated with
Table I. Features and properties
Alternate names AP23573; MK 8669
Originator ARIAD Pharmaceuticals






Breast cancer, cancer, endometrial cancer, non-small cell lung cancer, prostate cancer, sarcoma, solid tumors
Class Macrolides
Mechanism of action mTOR protein inhibitors
Chemical name Dimethylphosphinic acid rapamycin-40-O-yl ester
Molecular formula C53 H84 NO14 P
CAS registry number 572924-54-0
Route of administration IV, PO
Pharmacodynamics Causes tumor regression in animal models; inhibits mTOR levels among patients with various types of advanced
solid tumors: ridaforolimus and bicalutamide in combination synergistically inhibit growth of prostate cancer cell
lines, and inhibit mTOR and androgen receptor signaling pathways; oral dosing produces prolonged mTOR
inhibition in patients with solid tumors; inhibits the growth of erlotinib-resistant, KRAS-mutant non-small cell lung
tumors in mouse models; greater anti-tumor effect in a mouse model of breast cancer when combined with a
hypoxia-inducible pathway inhibitor
ATC codes
WHO ATC code C01D (vasodilators used in cardiac diseases), L01 (antineoplastic agents)
EphMRA ATC code C1D (coronary therapy excluding calcium antagonists and nitrites), L1 (antineoplastics)
Adverse events
Most frequent Anemia, hypokalemia, hyponatremia, mucositis, nausea, pruritus, thrombocytopenia
Occasional Anorexia, asthenia, diarrhea, fatigue, hypertriglyceridemia, hypocalcemia, vomiting
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predictable and manageable adverse events in 45
treatment-experienced patients with advanced,
progressive endometrial cancer. The most common
grade 1–2 adverse events were oral mucositis (or
mouth sores), fatigue, anemia, diarrhea, nausea,
asthenia, vomiting, and anorexia.[9]
2.2.3 Hematologic Malignancies
Phase II : Preliminary results from a phase II,
open-label, non-randomized, fixed-dose study of
intravenous ridaforolimus (once daily for 5 days)
in a total of 51 patients with refractory or re-
lapsed hematologic malignancies showed that the
drug had an acceptable adverse effect profile.
Patients were stratified into five disease-specific
groups and administered ridaforolimus (12.5mg
intravenously daily for 5 days every 2 weeks). The
most common treatment-related adverse events
were mucositis (total incidence of 32.1%), nausea
(21.4%), hypokalemia and hyponatremia (both
17.9%), and pruritus (14.3%). Other events oc-
curring in approximately 10% of patients in-
cluded diarrhea, hypertriglyceridemia, rash, and
hypocalcemia. Serious treatment-related adverse
effects included mucositis (three patients), diar-
rhea (two patients), syncope, neutropenic sepsis,
pulmonary infiltrates, and hypertriglyceridemia
(all one patient each). Patient enrollment and
treatment continues in this study.[39]
Phase I : No dose-limiting toxicities or serious
adverse events associated with ridaforolimus (12.5
or 15mg/day) occurred in a phase I trial involving
nine patients with recurrent malignant glioma. Re-
lated adverse events observed during pre-surgery
and cycle 1 dosing included hypertriglyceridemia/
hyperlipidemia (n= 3 patients), thrombocytopenia
(2), hypercholesterolemia (2), hyperglycemia (2),
diarrhea (2), and mucositis (1). Patients in this
study received ridaforolimus as a 30-minute intra-
venous infusion daily for 4 days prior to tumor
resection, followed by daily dosing for 5 days every
2 weeks on a 4-week cycle post-surgery recovery.[40]
2.2.4 Sarcoma
Phase II : Patients with advanced sarcoma
who were treated with intravenous ridaforolimus
experienced adverse events that were generally
mild or moderate and reversible. The most com-
mon adverse events were mouth sores, fatigue, in-
creased triglycerides, low red blood cell count,
and nausea. The patients in this phase II, open-
label, non-randomized, fixed-dose study received
ridaforolimus 12.5mg/day in a 5 days on, 9 days
off dosing schedule for ‡4 months.[25]
In a phase II study of ridaforolimus in pa-
tients with advanced sarcoma, the main dose-
related adverse events were mucositis, anemia,
thrombocytopenia, and maculopapular rash.
Most of these events were mild or moderate in
severity.[41]
Phase I : Ridaforolimus in combination with
paclitaxel was well tolerated with predictable and
manageable adverse events in a phase Ib study in
patients with progressive solid tumors.[8]
In a phase I trial of the oral formulation of
ridaforolimus in 58 patients with solid tumors,
the maximum tolerated dose was 10mg/day with
daily administration. The maximum tolerated
dose was 15mg/day with daily dosing for 3 out of
every 4 weeks. The dose-limiting toxicity was oral
mucositis. The maximum tolerated dose had not
been reached at 40mg/day in the dosing group
who received daily doses for 4 consecutive days
with 3 days off. Initial data showed that the three
dosing regimens were well tolerated and resulted
in similar treatment-related adverse events. The
adverse events experienced with the oral formula-
tion were the same as those of the intravenous
formulation.[42]
2.2.5 Solid Tumors
In a phase I study involving 17 patients receiv-
ing ridaforolimus and bevacizumab for the treat-
ment of solid tumors, the combination was well
tolerated at standard dose, with no dose-limiting
toxicity observed.[5] In further results, 6 of 17 pa-
tients experienced non-fatal bowel ulcers, perfo-
rations, and abscesses, thought to be related to
bevacizumab and/or ridaforolimus treatment. No
new or unexpected safety signals were observed.[29]
Ridaforolimus administered under a daily and
weekly dosing regimens have been well tolerated
by patients with various types of advanced solid
tumors in phase I trials. Overall, adverse events
were mild to moderate and easily managed. The
dose-limiting toxicity was severe oral mucositis.[37]
170 Adis R&D Profile
ª 2010 Adis Data Information BV. All rights reserved. Drugs R D 2010; 10 (3)
In a phase I dose-escalation trial of ridaforo-
limus in 24 patients with refractory or advanced
malignancies, frequent adverse events related to
the study drug-included mucositis, fatigue, rash,
diarrhea, anorexia, and nausea. These events were
mild to moderate in severity, and reversible. Pa-
tients received ridaforolimus on three schedules




Pharmacodynamic assays on samples collected
from patients with various types of advanced solid
tumors showed a good correlation of ridaforolimus
blood levels with inhibition of mTOR protein.
Combined phase I data demonstrated >90%mTOR
inhibition within 1 hour after dosing among all
patients administered ridaforolimus under a daily
and weekly dosing regimens. With the daily dos-
ing schedule, ridaforolimus maintained inhibi-
tion of mTOR activity for up to 10 days among
the majority of subjects.[37]
In a phase I dose-escalation trial involving
24 patients with refractory or advanced malig-
nancies, ridaforolimus (10–30mg/day) reduced
phosphorylated 4E-BP1 (P-4E-BP1) levels by >80%
1 day after dosing; levels remained reduced dur-
ing the 28-day dosing period. Of three patients
who had completed two cycles, anti-tumor ac-
tivity associated with the study drug was observ-
ed in two patients while one had stable disease.[38]
In the phase I/IIa dose escalation AP23573-05-
106 trial, oral ridaforolimus dosing resulted in
rapid, potent, and prolonged mTOR inhibition in
peripheral blood mononuclear cells, in 141 evalu-
able adults with refractory or advanced solid tu-
mors. Patients were randomized to one of seven
dosing regimens (10–100mg) in a 28-day cycle. P-
4E-BP1 levels decreased by 83–93% in 24 hours at
all dose levels. With the exception of the one daily
for 21 days regimen, >70%mTOR inhibition was
seen at most timepoints through the cycle. In the
24 patients receiving 40 mg once daily for 5 days,
mTOR was inhibited by >90% within 24 hours
after the first dose, and inhibition was maintained
at >75% throughout the cycle. This dosing regi-
men was selected for the phase III SUCCEED
trial. These results are comparable with those ob-
tained with intravenous ridaforolimus dosing.[33]
In a phase I trial involving nine patients with
recurrent malignant glioma, treatment with rida-
forolimus (12.5 or 15mg/day) was associated
with marked reduction in levels of phospho-S6 in
six of eight patients analyzed, with ‡95% reduc-
tion in three patients (range 50–100% reduction).
The authors suggested that this finding indicates
the study drug is reaching its target in the brain.
Patients received ridaforolimus as a 30-minute
intravenous infusion daily for 4 days prior to tu-
mor resection, followed by daily dosing for 5 days
every 2 weeks on a 4-week cycle post-surgery
recovery.[40]
Preclinical
In a mouse model of breast cancer, the anti-
tumor effect of ridaforolimus was enhanced
by combination with an agent that reduced the
level of hypoxia-inducible factor (HIF) in tumors.
In vitro, in cancer cell lines, mTORpathway activity
was detected in normoxic regions and HIF path-
way activity was present only in hypoxic regions;
this indicated that targeting both pathways simul-
taneously should achieve a greater anti-tumor effect
than separate targeting. Addition of HIF-1b knock-
down treatment to ridaforolimus administration
in a mouse model of breast cancer led to a 4-fold
decrease in tumor growth, whereas either treat-
ment alone resulted in a 2-fold reduction in tumor
growth.[43]
Ridaforolimus potently inhibited the growth
of erlotinib-resistant, KRAS-mutant NSCLC
tumors in three different mouse models. In a panel
of >100 lung-cancer cell lines, ridaforolimus show-
ed greater inhibition of tumor growth than erlotinib
in 79% of cell lines and 84% of KRAS mutant cell
lines.[11]
The combination of ridaforolimus and bica-
lutamide inhibited the growth of prostate cancer
cells in both cell culture and mouse models. The
combination also inhibited mTOR, and andro-
gen signaling pathways in prostate cancer cells,
evidenced by a decrease in prostate specific anti-
gen levels.[16] Further in vitro data showed that
ridaforolimus alone inhibited the growth of seven
Ridaforolimus 171
ª 2010 Adis Data Information BV. All rights reserved. Drugs R D 2010; 10 (3)
prostate cell lines, with sensitivity associated with
the loss of PTEN. Ridaforolimus plus bicaluta-
mide was strongly synergistic in both LNCaP
(androgen dependent) and C4-2 (androgen in-
dependent) cell lines, but only additive in RWPE-
1 (normal prostate epithelium) cells. Synergism
was demonstrated by the fact that p-S6 (Ser235/
236) levels in LNCaP and C4-2 were reduced
more by the combination, than by ridaforolimus
alone. Colony formation of C4-2 in anchorage-
independent conditions was inhibited by ~75%
with combination treatment, compared with
control. Ridaforolimus did not interfere with the
inhibition of androgen receptor expression by
bicalutamide.[15]
Ridaforolimus reduced tumor size in mice
bearing solid tumors by 46% compared with a
150% increase for animals not treated. Following
retreatment with ridaforolimus, further tumor
regression was observed.[44]
In animal models, ridaforolimus treatment at
an early stage caused the regression of persistent
human tumors by up to 90%. When treatment was
initiated at a later more aggressive stage, there were
still significant reductions in the rate of growth of
all six tumor types studied (brain, prostate, breast,
pancreas, lung, and colon cancers). Molecular
analysis of the tumors after removal showed that
the mTOR protein signaling was completely abol-
ished after a single low dose. This suppression
was found to last for 2–3 days. Researchers also
discovered that the anti-cancer activity of three
widely used chemotherapy agents was markedly





Updated preliminary clinical data fromaphase II
study with oral ridaforolimus (40mg/day, once daily
for 5 days) in combination with trastuzumab in
34 patients with resistant, metastatic, HER2-
positive breast cancer showed an objective res-
ponse rate of 15%, with five partial responses.
The clinical benefit response (objective responses
and durable stable disease) rate was 21% (median
duration of 4 months). Thirteen patients dem-
onstrated progressive disease.[4]
Earlier results from the phase II trial in 28 en-




intravenous infusion for 5 consecutive days every
other week for 28-day cycles) was effective in the
treatment of endometrial cancer in a phase II
study. The non-randomized study enrolled 45
patients with metastatic endometrial cancer, who
had received a median of two prior cytotoxic
chemotherapy regimens. Overall, 13 of 45 pa-
tients (29%) had a CBR defined as tumor regres-
sion or disease stabilization; 10% of patients had
a partial response.[8,9]
Glioblastoma
In a phase I study in patients with glio-
blastoma, low doses of ridaforolimus reduced the
growth of brain tumor cells by 40%. The reduc-
tion of tumor cell growth was achieved in brain
cancer cells both expressing and not expressing
epidermal growth factor receptor.[46]
Hematological Malignancies
Preliminary results from a phase II, open-label,
non-randomized, fixed-dose study of intravenous
ridaforolimus were promising. Data have been
presented for a total of 51 patients with refractory
or relapsed hematological malignancies who were
stratified into five disease-specific groups and
administered intravenous ridaforolimus (12.5mg
daily for 5 days for every 2 weeks). Indications of
anti-cancer activity were seen in four of five dis-
ease cohorts, with 20 of 50 evaluable patients
(40%) showing a partial response, minor response
or stable disease. Patient enrollment and treat-
ment continues in this study.[39]
Sarcoma
Phase II : In a phase II study, ridaforolimus
exhibited single-agent activity in 212 patients
with advanced sarcomas. Patients were enrolled
into four cohorts based on histologic subtypes;
there were no enrollment restrictions based on prior
therapies. Ridaforolimus (12.5mg, intravenous)
was administered daily for 5 days every 2 weeks.
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Table II. History
Date Comment
26 May 2010 Independent Data Monitoring Committee completes second interim efficacy analysis of the phase III SUCCEED
trial in metastatic sarcoma and recommends trial continue without modification to its final analysis[17]
5 May 2010 Merck and ARIAD restructure their collaboration agreement, grantingMerck full rights to ridaforolimus in Cancer[1,2]
25 March 2010 Merck and Ariad Pharmaceuticals initiate enrollment in a phase I trial in the US
25 March 2010 Phase I clinical trials in cancer in the US (PO)
5 March 2010 Phase II clinical trials in sarcoma in Japan (PO)
18 December 2009 ARIAD Pharmaceuticals completes enrollment in the phase III SUCCEED trial for metastatic soft-tissue and bone
sarcomas (809108162)
15 December 2009 Efficacy and adverse events data from a phase II trial in breast cancer presented at the 32nd Annual San Antonio
Breast Cancer Symposium (SABCS-2009)[4]
19 November 2009 Pharmacodynamics data from a preclinical trial in cancer presented at the 21st AACR-NCI-EORTC International
Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)[43]
21 September 2009 Interim efficacy and adverse events data from a phase I trial in solid tumors released by ARIAD Pharmaceuticals[29]
14 September 2009 Independent Data Monitoring Committee recommends that the phase III SUCCEED trial in sarcoma continue to full
patient enrollment
9 September 2009 Phase II clinical trials in non-small cell lung cancer in the EU (PO)
28 July 2009 Interim efficacy and adverse events data from a phase I trial in solid tumors released by ARIAD Pharmaceuticals[5]
28 July 2009 Interim efficacy and adverse events data from a phase II trial in breast cancer released by ARIAD
Pharmaceuticals[5]
7 May 2009 Merck and ARIAD complete enrollment in their phase I trial with ridaforolimus in combination with bevacizumab for
cancer in the US
21 April 2009 Pharmacodynamics data from preclinical trials in non-small cell lung cancer presented at the 100th Annual Meeting
of the American Association for Cancer Research (AACR-2009)[11]
28 February 2009 Phase II clinical trials in non-small cell lung cancer in the US (PO)
24 October 2008 Pharmacodynamics data from a preclinical trial in prostate cancer presented at the 20th-EORTC-NCI-AACR
Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)[16]
24 October 2008 Pharmacodynamics data from an in vitro study in Prostate cancer presented at the 20th EORTC-NCI-AACR
Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)[15]
24 October 2008 Pharmacodynamics data from the phase I/IIa AP23573-05-106 trial in solid tumors presented at the 20th EORTC-
NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)[33]
21 October 2008 Phase II clinical trials in combination with bicalutamide in prostate cancer in the US (PO)
31 August 2008 Phase I clinical trial in combination with MK 0646 in cancer in Spain (PO)
6 August 2008 Phase II clinical trials in endometrial cancer in Asia (PO)
6 August 2008 Phase II clinical trials in endometrial cancer in Australia (PO)
6 August 2008 Phase II clinical trials in endometrial cancer in the EU (PO)
6 August 2008 Phase II clinical trials in endometrial cancer in the US (PO)
30 July 2008 Phase II clinical trials in breast cancer in Chile (PO)
30 July 2008 Phase II clinical trials in breast cancer in the EU (PO)
30 July 2008 Phase II clinical trials in breast cancer in the US (PO)
30 June 2008 Phase I/II clinical trials in solid tumors in pediatric patients in the US (IV)
19 June 2008 Interim efficacy data from a phase I trial in sarcoma presented at the 44th Annual Meeting of the American Society
of Clinical Oncology (ASCO-2008)[47]
3 June 2008 Pharmacokinetics data from a phase I trial in solid tumors presented at the 44th Annual Meeting of the American
Society of Clinical Oncology (ASCO-2008)[34]
24 September 2007 Phase III clinical trials in sarcoma in the EU (PO)
24 September 2007 Phase III clinical trials in sarcoma in the US (PO)
Continued next page
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Table II. Contd
Date Comment
10 September 2007 ARIAD Pharmaceuticals receives special protocol assessment from the US FDA for a pivotal trial of deforolimus for
metastatic sarcomas
12 July 2007 ARIAD and Merck & Co. agree to jointly develop and commercialize deforolimus worldwide for cancer
11 June 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to
the adverse events and cancer therapeutic trials sections[8,9,24]
6 November 2006 Additional results from a phase II clinical trial in patients with advanced sarcoma have been added to the cancer
therapeutic trials section[23]
21 August 2006 ARIAD Pharmaceuticals has completed enrollment in the first stage of the two-stage, phase II trial for endometrial
cancer in the US and Europe
9 August 2006 Deforolimus is available for licensing outside of North America (http://www.ariad.com)
15 June 2006 Data presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2006) have been
added to the adverse events and cancer therapeutic trials sections[25]
4 May 2006 ARIAD Pharmaceuticals has completed enrollment in a phase II trial for sarcoma in the US and Europe
14 February 2006 ARIAD Pharmaceuticals has initiated enrollment in a phase Ib trial evaluating oral deforolimus plus doxorubicin for
advanced solid tumors, particularly certain sarcomas as well as breast, ovarian, and endometrial cancers in the US
14 February 2006 Phase I clinical trials in breast cancer in the US (PO)
14 February 2006 Phase I clinical trials in endometrial cancer in the US (PO)
14 February 2006 Phase I clinical trials in ovarian cancer in the US (PO)
14 February 2006 Phase II clinical trials in sarcoma in the US (PO)
11 January 2006 Data presented at the 47th Annual Meeting and Exposition of the American Society of Hematology (ASH-2005)
have been added to the adverse events and cancer therapeutic trials sections[39]
22 November 2005 Clinical data from a media release have been added to the adverse events section[42]
18 November 2005 Data presented at the 17th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
Therapeutics (AACR-NCI-EORTC-2005) have been added to the adverse events, pharmacokinetics, and cancer
pharmacodynamics sections[38,40]
15 November 2005 Deforolimus has received orphan drug status for soft-tissue and bone sarcomas in Europe
22 August 2005 Deforolimus has received orphan drug status for soft-tissue and bone sarcomas in the US
30 June 2005 Phase II clinical trials in endometrial cancer in Europe (IV infusion)
30 June 2005 Phase II clinical trials in endometrial cancer in the US (IV infusion)
27 May 2005 Phase II clinical trials in hematologic malignancies in the US (IV infusion)
20 May 2005 Data presented at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO-2005) have been
added to the adverse events and cancer therapeutic trials section[41,48]
6 May 2005 ARIAD has filed an IND with the FDA for an oral formulation for cancer
6 May 2005 Preclinical trials in solid tumors in the US (PO)
5 May 2005 Phase II clinical trials in prostate cancer in the US (IV infusion)
22 April 2005 Deforolimus has received fast track status for the treatment of soft-tissue and bone sarcomas in the US
5 October 2004 Data presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
(EORTC-NCI-AACR-2004) have been added to the adverse events, pharmacokinetics, cancer
pharmacodynamics and cancer therapeutic trials sections[37]
30 September 2004 Phase II clinical trials in sarcoma in Europe (IV infusion)
30 September 2004 Phase II clinical trials in sarcoma in the US (IV infusion)
25 August 2004 A study has been added to the cancer therapeutic trials section[49]
22 July 2004 ARIAD has initiated enrollment in two phase II trials for solid tumors in the US
30 June 2004 Phase I clinical trials in glioblastoma in the US (IV infusion)
30 June 2004 Phase II clinical trials in solid tumors in the US (IV infusion)
18 November 2003 Data from a media release have been added to the cancer therapeutic trials section[46]
Continued next page
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At the time of enrollment, 79% of patients had
received two prior treatments, and over 90% had
disease progression. The overall CBR rate was
29%, which included five partial responses (four
bone sarcoma, one malignant fibrous histiocyto-
ma). The median overall survival was 40.1 weeks
for the entire study population. In the subset of
patients who achieved CBR, the median overall
survival was 67.6 weeks.[24]
Phase I : Preliminary data from an ongoing
open-label, single ascending dose study evaluat-
ing 7 regimens of oral ridaforolimus showed that
the dose of 40mg daily for 5 days each week
provided clinical benefit response in 3 of 13 (23%)
patients with sarcomas and partial response in
two (15.4%) patients with liposarcoma or den-
dritic cells sarcoma. In 145 patients (85 with sar-
comas) receiving ridaforolimus, clinical benefit
response was classified as stable disease or better
lasting for at least 4 cycles of 28 days, and was
seen in all regimens in patients with several types
of sarcomas and a variety of carcinomas. The
40 mg daily for 5 days dose of ridaforolimus was
selected for a phase III study (SUCCEED) in
patients with metastatic soft-tissue and bone
sarcoma in the maintenance setting.[47]
Solid Tumors
Phase II :Final results from a non-randomized
phase II trial of ridaforolimus in patients
(n= 212) with advanced sarcoma demonstrated that
the drug produces clinical benefit and sympto-
matic improvement. Patients with either bone
sarcoma, leiomyosarcoma, liposarcoma, or other
soft-tissue sarcomas, received intravenous rida-
forolimus 12.5mg/day in a 5 days on, 9 days off
Table II. Contd
Date Comment
24 June 2003 Preclinical data from a media release have been added to the cancer pharmacodynamics section[45]
2 May 2003 Phase I clinical trials in cancer in the US (IV infusion)
20 January 2003 Deforolimus is available for licensing (http://www.ariad.com)
14 January 2003 ARIAD has filed an IND with the FDA in the US
18 April 2002 Preliminary data from a preclinical study has been added to the cancer pharmacodynamics section[44]
11 December 2001 New profile
11 December 2001 Preclinical development for cancer in the US (IV infusion)
Table III. Forecasts
InThought Probability of Approvala
Indication Approval Date Estimate inThought Approvability Index Last Update
Breast cancer NE 31% (NYR) 21 Jul 2009
Endometrial cancer NE 31% (NYR) 21 Jul 2009
Non-small cell lung cancer NE 31% (NYR) 21 Jul 2009
Prostate cancer NE 31% (NYR) 21 Jul 2009
Sarcoma NE 66% (NYR) 21 Jul 2009
Solid tumors NE 25% (NYR) 21 Jul 2009
a The Wolters Kluwer Health Approvability Index is a dynamic tool that assesses the progress of a drug candidate through clinical
development, evaluating strength of clinical data and trial design, benchmarked against historical parameters and likelihood to maintain
forward momentum. Points are assigned for specific line items relating to safety, efficacy, and other factors in each phase of clinical
development. Possible points total 100 upon drug approval, and are allocated in each phase according to the historical approval rate of
similar drugs, such that the current points of a drug relate to its probability of approval. In addition, a letter grade is assigned and reflects the
momentum of a drug candidate in its current phase, with ‘A’ indicating significantly above average/likely to progress, ‘C’ indicating average,
and ‘F’ indicating significantly below average/unlikely to progress. ‘NYR’ stands for ‘Not Yet Rated,’ indicating that the probability of
approval is based on historical approval rates for similar drugs according to indication, molecule type, novelty, and phase, but without
analyses of clinical data, trial design, and other factors specific to the individual agent.
NE = no estimate.
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dosing schedule for ‡4 months. CBRs, consisting
of sustained anti-tumor activity as defined by
RECIST (Response Evaluation Criteria in Solid
Tumours) guidelines, occurred in 29% of all
patients. CBR rates were not statistically signif-
icant among the four subgroups (bone sarcoma
30%; leiomyosarcoma 33%; liposarcoma 30%,
and other 23%). At 6 months, 24% of all patients
had survived with progression-free disease, which
was more than double that of historic control
data (8%) published by EORTC. The median
PFS time for all patients in the study was 15
weeks, compared with 7 weeks for EORTC his-
torical control patients. It was also noted that
results from one major center showed that 23 of
32 patients who had tumor-related symptoms,
such as pain, shortness of breath, and cough on
entry to the trial, showed clinically beneficial
symptom improvement during treatment with
AP 23573.[25,41,48]
Additional positive efficacy data from a phase
II trial in 61 (n = 212) evaluated patients with
advanced sarcoma showed that patients with
CBRs had PFS rate at 6 months of 70% and a
median PFS of 36 weeks. In comparison, the
overall trial population had PFS rate of around
24% at 6 months and themedian PFS of 15 weeks.
The CBR therefore can be used as a clinically
useful surrogate endpoint for PFS rate in patients
with advanced sarcoma.[23]
Phase I : In a phase I study involving 17 pa-
tients receiving ridaforolimus and bevacizumab
for the treatment of solid tumors, five patients
remain on study without disease progression.[5]
In further results, disease stabilization for at least
four cycles of treatment was demonstrated in 6 of
17 patients, giving a CBR rate of 35%. Tumor
stability for more than 8 months was observed in
four patients; two of whom remained on study
with stable disease.[29]
Ridaforolimus in combination with paclitaxel
had anti-tumor activity in patients with advanced
pharyngeal, pancreatic, ovarian, thyroid, and
breast cancers. The phase Ib dose-escalation trial
evaluated the optimal dosing regimen for the
combination therapy.[8]
According to updated data from two phase I
trials, patients with various types of relapsed
and/or refractory solid tumors demonstrated anti-
tumor responses with daily and weekly dosing
regimens of ridaforolimus. Among 49 evaluable
patients, tumor regression was evident in nine
patients (four partial responses with ‡30% tumor
shrinkage and five minor responses with 15–29%
shrinkage). Disease stabilization was achieved in
another 15 patients. Overall, 24 of 49 (49%) of
subjects attained anti-tumor responses (including
partial and minor responses as well as stable
disease) with a median response duration of
5 months that was extended to >18 months. Anti-
tumor responses were demonstrated in nine
different refractory and/or relapsed cancers, in-
cluding evaluable patients with sarcoma (5 of 5;
100%), kidney cancer (7 of 7; 100%), lymphoma
(1 of 1; 100%), and non-small cell lung cancer
(2 of 3; 67%).[37]
Previously, in the phase I trials among patients
with various solid tumors, ridaforolimus pro-
duced stable disease for at least 3 months in 50%
of evaluable patients in the daily dosing regi-
men and in 17% of the evaluable patients in the
weekly dosing regimen. Median duration of ac-
tivity in those patients was 5 months, extending
>12 months.[49]
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